News
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed the acalabrutinib 100mg tablets were bioequivalent to the acalabrutinib 100mg capsules.